Enlivex, a longevity pharmaceutical company, has secured $21 million in debt financing

According to market news, Changshou Medicine and the RAIN token asset pool Enlivex announced that they have obtained $21 million in debt financing from the New York institutional fund The Lind Partners.

The company stated that it will continue to implement its predictive market token asset pool strategy, adding approximately 3 billion RAIN tokens, which will be used to support the company's operational plans. Enlivex is a Nasdaq-listed company that is developing therapies for joint diseases such as osteoarthritis, while holding a large position in RAIN as part of the RAIN digital asset pool. RAIN is a decentralized predictive market protocol token deployed on the Arbitrum network, which determines outcomes through AI and employs a buyback and burn mechanism. Enlivex's stock price is currently around $1.05, down about 5% for the day.